News Column

Coca-Cola Study Results Suggest Potential Benefit to Plandai Biotechnology

Aug 27 2013 12:00AM

Marketwire

Tracker

BALTIMORE, MD -- (Marketwired) -- 08/27/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that a research study conducted by The Coca-Cola Company indicated that drinking polyphenol rich juice may have benefits associated with a positive change in a major protein that affects arterial health. These findings should be viewed as a positive event and as corroborating third-party evidence from the world's leading beverage producer and thus a boon to Plandaí Biotechnology (OTCQB: PLPL). Plandaí plans to introduce highly bioavailable extract products under the Company's Phytofare™ line that specifically contain these polyphenols which can be used in juices and other beverages.

Polyphenols are derived from natural extracts and have been the subject of extensive research due to high antioxidant activity and demonstrated capability to eliminate free radicals, or polluted cells. They are commonly found in green tea extracts, or green tea gallate catechin extracts, and carotenoid botanical extracts found in tomatoes and other 'colorful' vegetables.

The aforementioned study was conducted in a partnership with the University of Glasgow and Mosaiques Diagnostics, GmbH. Results demonstrated that the levels of 27 polypeptides, which are protein or amino acid chains in the arteries and elsewhere, increased by nearly 4 times in experimental candidates that consumed the polyphenol rich juices over time. Therefore, the study demonstrated that drinking green tea extract or carotenoid extract appears to improve arterial function at the molecular level.

Plandaí's Phytofare™ Catechin Complex and Carotenoid Complex have been formulated with a proprietary process that will enable the release of more of these polyphenol compounds versus the competitors. This product differentiation is created with superior bioavailability, or the measurement of an amount of a compound that is absorbed into the bloodstream. Normal extracts produce 1-10% bioavailability, while the Phytofare™ extract products have demonstrated 70% on average for bioavailability.

Plandaí is on target to begin production of the Phytofare™ Catechin Complex in powder form, topical cream, gel tabs, and a liquid by the end of 1Q14. The Company has partnered with several distributors in the U.S., Europe and Africa to sell market and distribute Plandai's Phytofare™ extracts in 1Q14 as well.

Plandaí's aggressive marketing campaign will reap major benefits from the message that beverages and other products that utilize the Phytofare™ products can provide superior levels of healthy ingredients, such as the polyphenols mentioned above. This differentiation should help the Company expand its market share and generate strong results in 2014.

Goldman Small Cap Research articles, reports, and updates on Plandai as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.



Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com





Source: Marketwire


Story Tools